|
Amino acid
|
Plasma (nM)
| |
Urine (nmol/mg creatinine)
|
|---|
|
Healthy controls
|
ASD
|
P value
|
Healthy controls
|
ASD
|
P value
|
|---|
|
FL
|
1489 (987–1863)
|
751 (361–1.570)
|
0.047
|
56.7 (33.8–128.7)
|
90.8 (42.4–167.9)
| |
|
CML
|
807 (587–1051)
|
853 (219–1222)
| |
26.2 (19.7–34.7)
|
33.1 (26.6–42.6)
|
0.016
|
|
CEL
|
402 (298–477)
|
420 (310–599)
| |
0.435 (0.202–0.848)
|
0.472 (0.180–0.940)
| |
|
G-H1
|
0.819 (0.553–1.26)
|
0.527 (0.366–0.959)
|
0.037
|
1.88 (1.11–3.04)
|
2.57 (1.53–3.75)
|
0.024
|
|
MG-H1
|
271 (176–475)
|
335 (213–500)
| |
18.6 (8.00–27.4)
|
24.5 (9.14–37.6)
| |
|
3DG-H
|
413 (303–637)
|
360 (280–434)
| |
2.06 (0.587–4.38)
|
2.92 (1.09–6.26)
| |
|
CMA
|
9.18 (6.67–12.5)
|
17.7 (13.2–24.8)
|
0.00052**
|
1.46 (0.636–1.97)
|
1.78 (1.14–2.91)
|
0.037
|
|
GSP
|
12.8 (7.4–17.1)
|
12.9 (9.3–22.0)
| |
1.58 (1.15–1.98)
|
1.53 (1.20–1.98)
| |
|
MOLD
|
1.79 (0.800–3.42)
|
1.10 (0.503–0.2.21)
| |
0.025 (0.013–0.050)
|
0.040 (0.017–0.068)
|
0.027
|
|
Pyrraline
|
22.0 (12.2–30.4)
|
24.2 (19.4–40.6)
| |
20.6 (14.9–44.2)
|
34.2 (22.7–72.5)
|
0.047
|
|
DT
|
0.501 (0.286–0.771)
|
0.676 (0.500–0.847)
| |
0.070 (0.058–0.085)
|
0.086 (0.075–0.109)
|
0.0022*
|
|
NFK
|
15.2 (12.5–18.1)
|
11.3 (6.23–14.3)
|
0.030
|
0.117 (0.084–0.231)
|
0.179 (0.107–0.238)
|
0.037
|
|
AASA
|
19.7 (16.9–29.1)
|
30.6 (21.1–46.4)
|
0.0063
|
1.08 (0.805–2.76)
|
1.80 (1.13–2.89)
|
0.040
|
|
GSA
|
73.9 (53.2–129)
|
109 (80.1–203)
|
0.039
|
17.3 (13.2–22.7)
|
34.5 (12.7–48.0)
|
0.0018*
|
|
3-NT
|
1.10 (0.90–1.26)
|
1.17 (0.79–1.58)
| |
0.0044 (0.001–0.010)
|
0.0077 (0.003–0.014)
| |
- Data are median (lower – upper quartile); healthy controls, n = 21–31, and ASD, n = 27–38. Significance (Mann-Whitney U)
- *P < 0.05 after Bonferroni correction of 15 applied
